Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Wild Type”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01294826
What this trial is testing

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer+3 more
Swedish Medical Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT07257653
What this trial is testing

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsRASBRAF+2 more
Zhejiang University 70
Testing effectiveness (Phase 2)Study completedNCT01892527
What this trial is testing

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Who this might be right for
Colorectal Cancer MetastaticC-met Overexpression
Armando Santoro, MD 43
Testing effectiveness (Phase 2)Study completedNCT02337946
What this trial is testing

Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

Who this might be right for
Colorectal Carcinoma
Takeda 164
Testing effectiveness (Phase 2)Ended earlyNCT01186705
What this trial is testing

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Who this might be right for
Colon CancerRectal Cancer
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00803647
What this trial is testing

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 20
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Early research (Phase 1)Ended earlyNCT02199223
What this trial is testing

Regorafenib + Panitumumab for Colorectal Cancers

Who this might be right for
KRAS and NRAS Wild-type Colorectal Cancer
University of Utah 2
Testing effectiveness (Phase 2)Study completedNCT01276379
What this trial is testing

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Who this might be right for
Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 221
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Testing effectiveness (Phase 2)Study completedNCT00444678
What this trial is testing

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerNeoplasm Metastasis
NYU Langone Health 36
Testing effectiveness (Phase 2)Study completedNCT01308840
What this trial is testing

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Who this might be right for
Biliary Tract CancerGallbladder Cancer
University of Rochester 31
Early research (Phase 1)Study completedNCT00879385
What this trial is testing

KRAS Wild-type Metastatic Colorectal Cancer Trial

Who this might be right for
Colorectal Cancer
University of Utah 21
Testing effectiveness (Phase 2)UnknownNCT02216487
What this trial is testing

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Who this might be right for
Metastatic Colorectal Cancer
Western General Hospital, Australia 45
Testing effectiveness (Phase 2)Study completedNCT01387880
What this trial is testing

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Herlev Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01652482
What this trial is testing

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Colorectal Cancer
Genentech, Inc. 135
Testing effectiveness (Phase 2)UnknownNCT04466254
What this trial is testing

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 75
Testing effectiveness (Phase 2)Ended earlyNCT01508000
What this trial is testing

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Who this might be right for
Colorectal Cancer MetastaticLiver MetastasesKRAS Wild Type Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC 44
Testing effectiveness (Phase 2)UnknownNCT03457896
What this trial is testing

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 35
Large-scale testing (Phase 3)Looking for participantsNCT06072781
What this trial is testing

Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Who this might be right for
Low Grade Serous Ovarian Cancer
Verastem, Inc. 270
Next Page